Roche Aktie

354,00 EUR -2,40 EUR -0,67 %

14:31:46

STU

354,80 EUR +2,40 EUR +0,68 %

14:56:49

GVIE

Roche jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.283,76 Mrd. EUR

KGV20,72Div. Rendite3,22%

WKN851311

ISINCH0012032113

SymbolRHHBF

Roche Aktien News

Sortieren:Datum Meistgelesen

03.06.25GlobeNewswireRoche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

31.05.25GlobeNewswireNew data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

30.05.25GlobeNewswireRoche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

23.05.25GlobeNewswireCHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer

23.05.25GlobeNewswireRoche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology

23.05.25GlobeNewswireNew two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients

22.05.25GlobeNewswireFDA approves Roche’s Susvimo for diabetic retinopathy

20.05.25GlobeNewswireRoche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

14.05.25GlobeNewswireRoche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis

13.05.25GlobeNewswireTen-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer

12.05.25PR NewswireRoche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub

06.05.25GlobeNewswireRoche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity

30.04.25GlobeNewswireCHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

29.04.25GlobeNewswireRoche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer

25.04.25GlobeNewswireNew England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission

24.04.25GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter

24.04.25GlobeNewswire[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche setzt Wachstumskurs mit Umsatzplus von 6% (CER) im ersten Quartal 2025 fort

23.04.25GlobeNewswireRoche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)

22.04.25GlobeNewswireRoche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years

14.04.25GlobeNewswireEuropean Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy

03.04.25GlobeNewswireRoche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025

02.04.25GlobeNewswireRoche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis

25.03.25GlobeNewswireRoche Annual General Meeting 2025

25.03.25GlobeNewswireRoche Generalversammlung 2025

17.03.25GlobeNewswireRoche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference

12.03.25GlobeNewswireRoche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight an

07.03.25GlobeNewswireRoche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston

05.03.25GlobeNewswireFDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis

02.03.25GlobeNewswirePhase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies

28.02.25GlobeNewswireCHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

20.02.25GlobeNewswireRoche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology

12.02.25GlobeNewswireFDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)

07.02.25GlobeNewswireNew England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis

04.02.25GlobeNewswireFDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness

31.01.25GlobeNewswireRoche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

30.01.25GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth

30.01.25GlobeNewswire[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2024 mit Verkaufswachstum von 7%; drittes Quartal in Folge mit 9% Wachstum

29.01.25GlobeNewswireChange to the Roche Enlarged Corporate Executive Committee

28.01.25GlobeNewswireRoche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer

27.01.25GlobeNewswireRoche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.